Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The uremic syndrome is characterized by retention of a large number of uremic toxins that are normally eliminated by the kidney. Despite significant advances in hemodialysis, standard hemodialysis with high flux membranes are limited by inadequate removal of uremic solutes such as middle molecules and protein-bound uremic toxins. Novel medium cut-off (MCO) membranes, were developed for better removal of conventional and large middle molecular weight uremic toxins, with insignificant albumin loss, but its long-term effects are unclear. We investigated whether MCO hemodialysis (HD) over one year could reduce middle and large middle molecule levels without albumin loss
Eleven patients with mean age 58.18±13.37 years, dialysis vintage 71.64 ± 84.62 months were included in 12 months observational study in hemodialysis with Theranova®400 and Theranova®500 dialyzers. Each patient was assessed 6 times, T0 with high-flux dialyzers, T1 – T5 with MCO at month 1,3,6,9 and 12, by measuring pre- and post-HD samples of myoglobin, free light chains kappa (FLC-k), Β 2-Microglobulin (β2M) and free light chains lambda (FLC-ʎ), albumin and hemoglobin. The removal rates of uremic toxins are represented as percentages, calculated as plasma concentration pre-HD minus post-HD, divided by plasma pre-HD and multiplied by 100. Comparative analysis for laboratory parameters between T0 and T5 was performed with pared T test and p< 0.05 was considered significant.
The data showed a higher significant average removal for all the middle uremic toxins with Theranova® dialyzers for myoglobin, β2M, FLC-k and FLC-ʎ (54 vs. 36; 66 vs. 22; 58 vs. 27 and 60 vs. 35% respectively). Significant albumin retention was observed with MCO and hemoglobin was sustained with both dialysis membranes (3.64±6.66 vs. -0.80±3.02, p=0.036; -1.97±3.64 vs. -1.66±3.26, p=0.807, respectively). In the 12 months follow up, the comparative analysis of the baseline uremic toxins between T0 and T5 showed significantly lower values for β2M, FLC-k, FLC-ʎ (35.72 ± 9.67 vs 30.07 ± 8.76, p=0.036; 207.98 ± 100.56 vs. 167.11 ± 71.95, p=0.0001; 230.44 ± 54.58 vs. 30.07 ± 8.76, p=0.004, respectively), myoglobin and albumin did not decline (263.10±117.43 vs. 265.69±301.90, p=0.969; 42.24 ± 4.08 vs. 41.11± 3.25, p= 0.365, respectively).
Our study demonstrates that the long term use of the novel MCO dialyser Theranova® appears to be safe and well-tolerated, without serious side effects or hypoalbuminaemia, with significant removal of middle molecules. These results need to be confirmed in larger randomized clinical trials
